Lilly’s rheumatoid arthritis pill rejected by regulators
The drug, which has the proposed brand name Olumiant and is approved for use in Europe, was expected to be a big seller.
Pharmaceutical
Articles
FDA issues warning to local doctor for breaking protocol on drug trial
The federal agency says the Indianapolis doctor studying Pfizer’s Chantix last year failed to keep accurate records and used patients who didn’t meet the trial requirements.
Blame game over drug prices escalates with new ad campaign
Broadening its efforts to defuse outrage over skyrocketing prices, the pharmaceutical industry’s lobbying association has started an advertising campaign urging insurers to share with customers more of the benefits of rebates they’ve negotiated.
Eli Lilly chasing psoriasis jackpot with Taltz
Taltz, which hit the market last year, is taking on an armful of older treatments, including creams, lotions, pills and injectables, such as Amgen’s Enbrel and AbbVie’s Humira.
Pharma stocks slide after new tweet from Trump on drug prices
Share of Eli Lilly and Co. and numerous other drug industry stocks fell Tuesday morning after the president sent a tweet promising to lower medicine costs for American people.
As pricing criticism mounts, Lilly, other drugmakers roll out pay for performance
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Merck stops Alzheimer’s study after ‘no chance’ of benefit
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
Indy-founded drug firm lands nearly $23M to fight rare disease
Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.
Dying patients have Pence’s backing on ‘right to try’ policy
Vice President Mike Pence may have just picked another fight with pharmaceutical companies—one that doesn’t involve drug prices.
UPDATE: Trump tells drugmakers, including Lilly, their prices are ‘astronomical’
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.
Carmel biotech firm scores major deal with pharmaceutical giant
A small Carmel-based biotech firm has signed a deal with international drug company Allergan Plc that is worth at least $50 million and could grow to more than $2 billion under the best-case scenario.
2016 TOP STORIES: Lilly Alzheimer’s drug fails in high-stakes trial
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
Lilly partners with AstraZeneca on another Alzheimer’s treatment
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
Pharma stocks slide after Trump’s vow to control drug costs
President-elect Donald Trump promised to drive down the cost of medicines, defying investors who saw a boon in his election last month and injecting himself again into a contentious economic debate.
Pharmaceutical firm plans $10.4M in new equipment, 60 jobs
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
At Eli Lilly, tears, heartbreak and renewed determination
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
Pharmacy grads still finding jobs, but it’s getting tougher
Pharmacy grads used to have their pick of six-figure jobs. But competition stiffened after dozens of new schools opened, sharply increasing the supply of newly minted pharmacists.
Lilly shares slip after Bernie Sanders criticizes insulin prices
Makers of insulin became the latest target for Sen. Bernie Sanders, who has been going after pharmaceutical companies one by one over the issue of high U.S. drug prices.
Drug firms fighting ‘tooth and nail’ against California ballot measure
Drugmakers including Eli Lilly and Co. are becoming increasingly vocal in fighting a California ballot proposition designed to bring down prices on prescription medicine.
Lilly cancer drug lands accelerated FDA approval
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.